Abstract-Tissue factor (TF) is the high-affinity receptor and cofactor for factor
T issue factor (TF) is a transmembrane protein that functions as a high-affinity receptor for factor (F)VII and FVIIa. [1] [2] [3] [4] [5] [6] The TF-FVIIa complex is the primary activator of the coagulation protease cascade. TF is required to stabilize the catalytic site of FVIIa on a plasma membrane (PM) to allow optimal interaction with its substrates FIX and FX. There are many excellent reviews on TF. [1] [2] [3] [4] [5] [6] The goal of this review is to summarize our current knowledge on the roles of TF in hemostasis and thrombosis.
Brief History of the Major Advances in TF Research
The original extrinsic coagulation system consisted of 4 factors: fibrinogen (FI), prothrombin (FII), thromboplastin (FIII, TF), and Ca ++ (FIV). This basic blood coagulation system is present in jawless fish that diverged over 450 million years ago. 7 Morawitz was the first to show that conversion of prothrombin to thrombin in plasma was induced by tissue thromboplastin. 8 Indeed, TF was originally simply a laboratory reagent derived from tissues, such as the placenta, that was added to plasma to measure the prothrombin time. Early studies showed that TF was a protein that required phospholipid for its activity. 9, 10 It was subsequently purified by 2 groups in the 1970s. 11, 12 In 1987, the TF cDNA was cloned by 4 groups, [13] [14] [15] [16] which led to an explosion of research on TF. The TF gene was cloned in 1989, which allowed analysis of its transcriptional regulation. 17 The crystal structure of the extracellular region was found to consist of 2 immunoglobulin-like domains, 18 and was the first structure of a member of the class 2 cytokine receptor family. In 1996, 3 groups reported that deletion of the TF gene in mice leads to universal death during embryonic development or shortly after birth, indicating that TF is essential for survival.
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Coagulation Protease Cascade
Hoffman and Monroe proposed a new cell-based model of coagulation with a TF-positive cell and activated platelets that involves initiation, amplification, and propagation. 22 We have adapted this model and have divided the phases of blood coagulation into TF-FVIIa-dependent initiation, inhibition of the TF-FVIIa complex by TF pathway inhibitor (TFPI) and amplification of thrombin generation.
After vessel injury or tissue trauma the TF-FVIIa complex is the spark that triggers blood coagulation by activating both FX and FIX. FVII bound to TF is rapidly activated by a variety of coagulation proteases, although autoactivation by trace amounts of FVIIa may be the primary pathway. 23 Several studies have shown that the TF-FVIIa complex can activate FIX in vitro. [24] [25] [26] One study analyzed the activation of FIX and FX in an in vitro system and found that FIXa was the major substrate of the TF-FVIIa complex. 27 Moreover, TF-FVIIa activation of FIX is important in vivo because a point mutation at residue 182, which led to reduced interaction with the TF-FVIIa complex without affecting activation by FXIa, was associated with a mild form of hemophilia B. 28 In addition to the TF-FVIIa complex, a recent study showed that the TF-FVIIa-FXa complex can activate FVIII, which would provide additional levels of FVIIIa during the initiation phase. 29 Formation of the prothrombinase complex (FVa-FXa) generates small amounts of thrombin in the initiation phase. Activated platelets are an important source of FVa that may contribute to the initiation phase of blood coagulation. 30 The final part of the initiation phase is thrombin activation of the cofactors FV and FVIII and platelets via protease-activated receptors (PARs). The TF-FVIIa complex is then rapidly inhibited by TFPI in a FXadependent manner.
In the amplification phase the tenase complex (FVIIIaFIXa) is assembled on the surface of activated platelets and generates additional FXa. The prothrombinase complex is also assembled on the surface of activated platelets. Thrombin activation of FXI also allows additional activation of FIX. 31 The net result is the generation of large amounts of thrombin. Thrombin cleaves fibrinogen to fibrin monomers that are cross-linked by the transglutaminase FXIIIa, which is activated by thrombin. In addition, thrombin activates additional platelets.
Blood-Borne TF
Blood was not thought to contain functional TF because of its high procoagulant activity (PCA). However, in 1999, Giesen et al 32 reported the presence of blood-borne TF that contributed to thrombus formation when native blood was flowed over collagen-coated slides. In contrast, Butenas et al 33, 34 could not detect active TF in whole blood. One difference between these studies is flow, which may be required to reveal the functional activity of encrypted or intracellular TF. To date, the accumulated evidence suggests that there are very low levels of TF in blood but this TF is either encrypted or inhibited and must be activated in some way to activate coagulation. Interestingly, one study reported TF staining throughout thrombotic clots but only at the edges of hemostatic clots in mice, and suggested that blood-borne TF may contribute to thrombosis but not hemostasis.
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TF Expression by Circulating Cells and Vascular Endothelial Cells
It has been reported that ≈1.5% of CD14 + monocytes in humans express low levels of intracellular TF under resting conditions. 36 Exposure of monocytes to bacterial lipopolysaccharide (LPS) in vitro or in vivo leads to a rapid and transient expression of TF [37] [38] [39] (Table 1 ). This induction is mediated by the transcription factors AP-1 and NF-κB. [59] [60] [61] We think that TF is expressed by monocytes as part of the innate immune response presumably to facilitate clot formation to limit the dissemination of pathogens.
Osterud and Bjorklid 62 proposed that TF is exclusively expressed by circulating monocytes in blood of healthy individuals and that under pathological conditions monocytes release TF-positive microvesicles that bind to other cells, such as activated platelets, neutrophils, and endothelial cells (ECs). Indeed, in vitro studies support the notion of the transfer of monocyte-derived microvesicles to platelets and neutrophils. [63] [64] [65] [66] However, it is difficult to make any conclusions about the origins of TF on cells in vivo because of the fact that microvesicles can transfer antigens, such as TF, between cells. The most definitive way to determine which cells are making TF is to measure TF mRNA by in situ hybridization.
TF expression by platelets, neutrophils, and eosinophils is controversial (Table 1) . We found that unstimulated platelets contain TF pre-mRNA that is spliced to TF mRNA after activation of the platelets, although this process is relatively slow (≈30 minutes). 42 Other studies have reported variable levels of TF mRNA and protein in unstimulated platelets but an increase of TF mRNA and protein in activated platelets. [43] [44] [45] 67 Other groups failed to detect TF expression in platelets. [49] [50] [51] A recent study convincingly showed that a megakaryocyte line expressed TF pre-mRNA, TF mRNA and TF protein and released a subset of TF-positive platelets. 46 Interestingly, the megakaryocyte cell line contained higher levels of TF mRNA versus TF pre-mRNA whereas platelets derived from the cells had more TF pre-mRNA. Similar results were observed with megakaryocytes derived from CD34 + cells. It should be noted that the megakaryocyte cell line expresses very low levels of TF (90±15 pg/mL), which is <0.1% of the level of TF observed in a human pancreatic cell line. 68 Several studies have found TF-positive platelets in patients with acute coronary syndromes and diabetes mellitus. 47, 48 Because of the time needed to splice TF pre-mRNA and express TF is seems more likely that platelet TF contributes to thrombosis rather than hemostasis. 69 TF has been reported to be expressed by neutrophils, eosinophils, and T-cells in vitro and in vivo (Table 1) . 52, 53, 55, 56, 58 However, the Osterud group failed to detect TF expression in human neutrophils or eosinophils. 54 (Erlich J and Mackman N, unpublished data, 2000) . In addition, we found that deletion of TF in neutrophils reduces LPS-induced activation of coagulation in mice (Grover and Mackman, unpublished data, 2018) .
TF expression by ECs is readily demonstrably in vitro but it is more difficult to demonstrate TF expression by ECs in vivo in part because of the very low levels of expression. [74] [75] [76] Typically, studies are performed with cultured ECs, such as human umbilical vein ECs. It is often assumed that these cells can be used as models of the variety of ECs present in different vascular beds in vivo, which is unlikely to be true. We and others have shown that human umbilical vein ECs express TF in response to a variety of different agonists and this induction is mediated by activation of NF-κB. 41, 77, 78 The most convincing examples of TF expression in vivo are by ECs in the splenic microvascular, at arterial branching areas in septic baboons and in the lungs of sickle cell disease (SCD) mice. [79] [80] [81] [82] Another study reported TF expression in ECs in the glomeruli of endotoxemic mice. 83 One difficulty with these immunohistochemical studies is TF staining of a given cell does not mean that the cell expressed TF because this signal could be because of the binding of TF-positive microvesicles from other cells, such as activated monocytes.
Transcriptional and Post-Transcriptional Regulation of TF
Because of the large amplification of the coagulation cascade, TF-dependent activation of blood coagulation needs to be tightly regulated to maintain hemostasis and prevent thrombosis. The first level of control is at the level of TF gene expression. For instance, high TF expression is restricted to cells not in direct contact with blood. 79, 84 Additionally, TF PCA is regulated at the post-translational level. TF exists in 2 states: encrypted TF present on unperturbed cells and deencrypted TF on damaged cells. 85 FVIIa can bind to TF on cells under resting conditions but the level of TF PCA activity is very low. However, activation or disruption of cells dramatically increases TF PCA. 86, 87 In terms of hemostasis, this rapid increase in TF PCA would enhance the activation of coagulation at sites of vessel injury and cell damage. Several mechanisms have been proposed for the posttranslational control of TF PCA. 6 The most popular mechanism is that phosphatidylserine interacts with TF resulting in a conformational change and enhanced PCA on cell surfaces. 88 In support of this mechanism, TF PCA is enhanced by the addition of phosphatidylserine to reconstituted phospholipid vesicles. 86, 89 Additionally, the pseudosubstrate TFPI-FXa bound to the TF-FVIIa complex on perturbed cells exposing phosphatidylserine but not to the complex on unperturbed cells, which suggested that activation of the cells leads to a change in conformation of TF that enables engagement with substrate.
88 Figure 1A shows a summary of the proposed phosphatidylserine-dependent model of TF de-encryption. Briefly, the PM of eukaryotic cells has an asymmetrical distribution of phospholipids with negatively-charged phospholipids, such as phosphatidylserine and phosphatidylethanolamine, sequestered in the inner leaflet and neutrally charged phospholipids, such as phosphatidylcholine and sphingomyelin, present in the outer leaflet. Cellular damage leads to loss of the PM asymmetry and exposure of negatively-charged phospholipid, such as phosphatidylserine, on the cell surface. In a recent study, molecular dynamic simulations were used to generate a model of membrane-bound TF-FVIIa complex using soluble TF, which lacks the transmembrane domain. 90 It was found that "the direct interaction of the phosphatidylserine headgroups with specific residues on soluble TF most likely also affect the conformation of these residues." Further, they concluded that "lipids might have an active direct role in de(-en)cryption of soluble TF." 90 Phosphatidylserine exposure on the cell surface also facilitates the binding of coagulation proteins (FII, FVII, FIX, and FX) with positively-charged γ-carboxyglutamic acid (Gla) domains and assembly of the cofactor/protease complexes. In contrast to phosphatidylserine-rich lipid surfaces, phosphatidylcholine-rich lipid surfaces confer relatively limited TF PCA suggesting that phosphatidylcholine maintains TF in an encrypted state. 91, 92 More recently it was reported that sphingomyelin, a major phospholipid in the outer leaflet of the PM, helps maintain the TF-FVIIa complex in an encrypted state in resting cells. 93 Cellular activation leads to translocation of acid sphingomyelinase to the PM and hydrolysis of sphingomyelin enabling de-encryption of the TF-FVIIa complex ( Figure 1A) .
TF PCA is also regulated by oxidation of an allosteric disulfide bond ( Figure 1B ). TF has 2 pairs of disulfide bonds, one in the N-terminal (Cys49-Cys57) and the other in the C-terminal (Cys186-Cys209) domain. An early study demonstrated that TF PCA was reduced ≈3-fold when either Cys186 or Cys209 were mutated whereas there was no effect of mutating either Cys49 or Cys57. 94 This suggested that formation of the Cys186-Cys209 disulfide bond was important for TF PCA. A later study proposed that cryptic TF contains unpaired cysteine thiols at positions 186 and 209, and that activation involves formation of a Cys186-Cys209 disulfide bond. 95 Protein disulfide isomerase has been proposed to be an important regulator of TF redox state and activity. [96] [97] [98] For instance, inhibition of protein disulfide isomerase reduces TF PCA in vitro. 97, 99 However, there are several unresolved issues with the allosteric disulfide bond hypothesis. First, the disulfide bond must be formed before binding of FVII/FVIIa to TF because this region of TF is buried at the interface between TF and FVII/FVIIa. 100 Second, as noted by Bach and Monroe 100 "there is no direct quantitative evidence for free thiols in TF." Finally, protein disulfide isomerase may also indirectly affect TF PCA by promoting exposure of phosphatidylserine. 101 It should be noted that studies of deencryption of TF PCA have largely used cultured cells and it is difficult to know what mechanism(s) occur in vivo.
TF Inhibitors
After the cloning of the TF cDNA in the late 1980s there was a lot of excitement about the prospect of using TF inhibitors as new antithrombotics. 102 This is summarized by a comment by Dr Golino in 2002 "many experimental studies have demonstrated that inhibitors of TF:FVIIa PCA are powerful inhibitors of in vivo thrombosis and that this approach usually results in less pronounced bleeding tendency, as compared with other more classical antithrombotic interventions." 102 There are 5 main classes of human TF (hTF) inhibitors: anti-TF antibodies that either compete with FVII/VIIa binding or bind to the TF-FVIIa complex, recombinant TFPI, active siteinhibited FVIIa (FVIIai), nematode anticoagulant protein C2 (NAPc2), and Ixolaris. NAPc2 is an 85-amino acid protein isolated from the hematophagous hookworm. 103 It acts in a similar manner to TFPI by first binding to FXa and then the NAPc2-FXa complex binds to TF-FVIIa. Ixolaris was isolated from a tick salivary gland and contains 2 Kunitz domains. 104 Unlike TFPI, it binds to zymogen FX and then the complex inhibits the TF-FVIIa complex.
These inhibitors have been used in preclinical and clinical studies of acute coronary syndromes, sepsis, HIV infection, and acute lung injury/acute respiratory distress syndrome. The effect of NAPc2 was examined in patients with non-ST-segment-elevation acute coronary syndromes and seems to be safe because it did not significantly affect major or minor bleeding (3.7% versus 2.5%). 105 However, no further studies have been performed using NAPc2. A recent study showed that Ixolaris reduced levels of plasma D-dimer in monkeys infected with simian immunodeficiency virus. 106 Recombinant TFPI reduced lethality in a baboon model of sepsis. 107 However, there was no effect on all-cause mortality in patients with severe sepsis and there was an increased risk of bleeding. 108 Early administration of a monoclonal antibody against TF reduced sepsis-induced respiratory and renal failure in baboons. 109 The success of this preclinical model led to a clinical trial that examined the effect of FVIIai in patients with acute lung injury/acute respiratory distress syndrome. Unfortunately, the trial was stopped early by the Safety Committee because of increased mortality in the group receiving the highest dose of FVIIai. 110, 111 In addition, patients with the higher doses of FVIIai also had a trend to increased risk of serious bleeding. In retrospect, given the central role of TF in lung hemostasis, these results are not unexpected. Based on these studies, it seems unlikely that TF inhibitors will be used clinically in the future.
TF-FVIIa-Dependent Signaling
The TF-FVIIa complex has both PCA and signaling activity. The localization of TF on the cell surface seems to regulate these functions with the signaling form of TF being located in lipid rafts. 112 The signaling form of the TF-FVIIa complex also interacts with β 1 integrins. 113 A recent study identified the binding motif in the FVIIa protease domain that mediates the interaction with β 1 .
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The TF-FVIIa complex and downstream coagulation proteases, such as thrombin, activate cells by cleavage of G protein-coupled PARs. This family consists of 4 members, PAR1-4.
115 PAR2 can be activated by the TF-FVIIa and TF-FVIIa-FXa complexes as well as FXa, whereas PAR1 is activated by thrombin and FXa. 116 TF-FVIIa-dependent signaling has been mainly studied in cancer. 117 Studies have shown that PAR2 activation by TF-FVIIa induces proangiogenic and immune modulating cytokines, whereas PAR1 activation by thrombin or the TF-FVIIa-FXa complex contributes to the metastatic tumor environment.
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Alternatively Spliced TF
A soluble form of TF can be generated by alternative splicing of the TF gene where exon 5 is skipped. 118, 119 This alternatively spliced TF lacks residues required for interaction with FX, the allosteric disulfide in the C-module and the transmembrane domain that dramatically reduce its PCA. [120] [121] [122] However, alternatively spliced TF has PCA in the presence of phospholipids. 123 Moreover, alternatively spliced TF plays a role in cancer biology by promoting angiogenesis and proliferation of tumor cells via interacting with integrins containing β 1 and β 3 .
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Hemostasis Hemostatic Defects in Mice and Humans Deficient in Different Coagulation Proteins
Factors of the coagulation cascade can be divided into 4 groups based on the phenotype of mice deficient in each of the factors (Figure 2 ). Group 1 contains factors of the extrinsic pathway (TF, FVII, FV, FX, and FII). Complete deficiencies of any of these proteins in mice leads to universal death during embryonic development or shortly after birth. [19] [20] [21] [126] [127] [128] [129] [130] Group 2 contains FVIII and FIX. Complete deficiencies of these proteins in mice is not lethal but is associated with impaired hemostasis in a tail transection model and a saphenous vein injury model. [131] [132] [133] [134] [135] Group 3 contains FXI. A complete deficiency of this protein in mice is not lethal but these mice have a mild hemostatic defect in a saphenous vein injury model. 135, 136 Group 4 contains FXII. In contrast to the hemostatic defects in mice with deficiencies in proteins in the other groups, mice with a complete deficiency in FXII have no hemostatic defects ( Figure 2) . 137 However, FXII-deficient mice are protected in thrombosis models. 138, 139 Unlike mouse studies where gene inactivation leads to a complete deficiency of a given protein, humans with deficiencies in different coagulation proteins usually have residual amounts of functional protein. To date, there are no reports of humans with a deficiency of TF. In contrast, rare inherited bleeding disorders occur because of deficiencies in FII, FVII, FX, FXI, and FXIII, 140 although the estimated prevalence of these disorders is very low (between 1 and 2 per 10 6 individuals). 140 Individuals with deficiencies in FII, FX, or FV most often bleed in the skin and mucus membranes and those with the lowest levels of the different coagulation factors have intracranial bleeds. 140 In terms of the coagulation cascade, the most frequent congenital bleeding disorders in the general human population are caused by deficiencies in FVIII (hemophilia A) and FIX (hemophilia B). The prevalence rates of these bleeding disorders is 1/5000 male births. 140 Hemophilia A and B patients are prone to spontaneous bleeding in the joints and skeletal muscle. 141 FXI deficiency is rare (1 per 100 000) and individuals with FXI deficiency rarely exhibit spontaneous bleeding but have an elevated risk of bleeding after surgery such as tooth extraction. The TF-FVII complex plays an essential role in hemostasis. TF is expressed by perivascular cells, such as adventitial fibroblasts and pericytes, and at body surfaces, such as keratinocytes in the skin. 79, 84, 145 Drake et al 79 proposed that TF formed a hemostatic envelope around blood vessels and body surfaces. Initially, it was thought that the physical separation of TF from blood meant that the TF-FVIIa complex was only formed after vascular injury. However, a recent study reported that perivascular TF was prebound to FVII/FVIIa in the dermal vasculature. 146 Indeed, coagulation factors, such as FVII, leak into the extravascular space at levels roughly proportional to their size. 147, 148 The presence of a preformed TF-FVIIa complex would allow rapid activation of clotting after vessel injury. In contrast to dermal vessels, there is a high proportion of free TF (non-FVII bound) present in the brain parenchyma and cerebral vessels. 149 This difference is likely because of the lower permeability of the blood-brain barrier. The high levels of TF in the brain may compensate for this the lower level of preformed TF-FVIIa complex around the cerebral vasculature.
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Use of Transgenic Mice to Study the Role of TF in Hemostasis
As noted above, TF −/− and FVII −/− mice die during embryonic development or shortly after birth, which means that they cannot be used to study the roles of the TF-FVIIa complex in hemostasis in different organs in adult mice. [19] [20] [21] 126 To circumvent the lethal phenotype of these mice, we and others have generated mice that express low levels of either TF or FVII. 150, 151 We rescued mTF −/− embryos by expressing hTF from a hTF minigene. 150 These mice (mTF −/− , hTF + minigene) are referred to as low TF mice and express ≈1% to 2% of wildtype TF levels. Rosen et al 151 generated transgenic mice with low levels of FVII by targeted replacement of the FVII gene with a FVII cDNA. Remarkably, the phenotypes of low TF and low FVII mice are similar supporting the notion for a central role for the TF-FVIIa complex in hemostasis. 152, 153 Consistent with a role for TF in hemostasis, low TF mice exhibit prolonged bleeding after various hemostatic challenges. For instance, low TF mice have increased bleeding after tail transection (Table 2) . 152 In addition, low TF mice had prolonged bleeding times in the saphenous vein mechanical injury model and after repeated vessel injury in the saphenous vein laser injury model 161 ( Table 2 ; unpublished data, 2018). Interestingly, the hemorrhage observed in low TF mice in these models is not as severe as FIX −/− mice. Low TF mice also have excess bleeding after a full thickness skin punch. 162 We determined the effect of combining low levels of TF with a complete deficiency of other procoagulant factors or PAR4, which is the main thrombin receptor on mouse platelets. Consistent with the importance of FIX in hemostasis, mice with a combination of low levels of TF and an absence of FIX do not survive to wean. 163 Our recent studies indicate that low TF, FIX −/− mice survive embryonic development but die shortly after birth (Grover and Mackman, unpublished data, 2018). In contrast, we found that the majority of low TF,
FXI
−/− mice survive to wean (Grover and Mackman, unpublished data, 2018).
Mice with low levels of TF but lacking PAR4 survive to wean but exhibit reduced survival because of fatal bleeds in the lung and brain compared with low TF, PAR4 +/+ controls. 154 Interestingly, the bleeding phenotype observed in low TF mice in the laser injury model was increased after administration of the P2Y12 inhibitor clopidogrel at a dose that had a minimal effect on bleeding time in wild-type mice. 161 These data suggest that TF-dependent thrombin generation leads to both fibrin deposition and platelet activation that act co-operatively to form and stabilize the hemostatic plug.
Two other transgenic mouse lines have been made that express hTF in place of mouse TF. Chromosomal vector hTF mice (mTF −/− , hTF + chromosomal vector) express hTF from a vector consisting of the majority of chromosome 1, whereas hTF knockin mice were generated by gene targeting that replaced the mouse TF gene with the hTF gene. 157, 164 Mouse FVIIa binds with high affinity to both mouse and hTF but the association of human FVIIa with mouse TF is significantly lower than with hTF. 165 Indeed, we found a 6-fold reduction in FXa generation when we used human FVIIa with mouse TF compared with hTF. 166 These studies indicate that hTF can be used to replace mouse TF but not vice versa, although we do not know about interactions of hTF with mouse β 1 integrins. Finally, we generated mice with a floxed TF gene (TF fl/fl ) that when crossed with mice expressing Cre recombinase under the control of a specific promoter leads to cell type-specific deletion of the TF gene (Table 3) . 
Hemostasis Requires a Balance Between TF and TFPI
TFPI is the major physiological inhibitor of the TF-FVIIa complex and shuts down the initiation of the clotting cascade. [173] [174] [175] [176] [177] There are 2 forms of TFPI: TFPIα and TFPIβ. TFPIα contains 3 Kunitz domains where domain 1 binds to FVIIa and domain 2 binds to FXa. TFPIβ is alternatively spliced form that contains Kunitz 1 and 2 with a different C-terminus that mediates anchoring to the membrane via a glycosylphosphatidyl inositol linkage. Similar to a TF −/− mice, a complete deficiency of TFPI is universally lethal during embryonic development. 178 
TFPI
−/− embryos had intravascular thrombi and fibrin(ogen) deposition in the liver and seem to exhibit a consumptive coagulopathy with secondary bleeding. There are no reports of TFPI-deficient humans. , TFPI −/− survived embryonic development but succumbed to perinatal bleeding because of an absence of FVII. We found that low levels of TF rescued TFPI −/− embryos from embryonic lethality and allowed the generation of viable TFPI −/− adult mice that survived for >6 months without any adverse phenotype. 155 Conversely, reducing the levels of TFPI dose-dependently reduced the hemostatic defects in low TF mice. 155 A similar principle of rebalancing clotting has been applied to restore hemostasis in hemophilic mice. For instance, inhibition of TFPI in hemophilia A mice reduced bleeding in a tail vein model. 180 TFPI inhibitors are currently being developed for the treatment of patients with hemophilia.
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Tissue-Specific Hemostasis
TF is expressed in an organ-specific manner with high levels in the brain, lung, heart, uterus, and placenta, and low levels in skeletal muscle and joints. 183 This pattern of expression suggests that TF provides additional hemostatic protection to a select group of vital organs. For instance, blood vessels in the heart and lung may need additional hemostatic protection because they are more likely to be injured by the mechanical movement of these organs. In contrast, tissues that have low levels of TF are likely more dependent on the intrinsic pathway to generate thrombin for hemostasis. Indeed, hemophilia A and B patients are prone to bleeding into joints and skeletal muscle and inhibitor patients receive FVIIa as a bypass agent to boost the extrinsic pathway. Low TF mice have been used to study the role of TF in tissuespecific hemostasis and exhibit spontaneous hemorrhaging in various tissues (Table 1) .
Lung
The lung contains high levels of TF. 184 Epithelial cells are the primary site of TF expression in the lung. 61 Mice with TF deleted in epithelial cells (TF fl/fl , SPCcre; Table 3 ) have significantly reduced baseline levels of TF compared with controls. 160, 171 LPS and influenza A virus infection increase TF expression in the lung of mice and specifically in epithelial cells. 61, 159, 160, 171, 184 LPS and influenza A virus did not increase TF expression in TF fl/fl , SPCcre mice. These studies indicate that the increased TF expression in epithelial cells is response to infection may provide additional hemostatic protection in the face of an infection.
Low TF mice exhibit a high incidence of fatal lung hemorrhages (≈50%) when backcrossed 7 generations onto the prohemorrhagic C57BL/6 background. (Table 2) . 154, 155 This indicates that lung hemostasis is impaired in low TF mice. In addition, our standard low TF (backcrossed 6 generations to the C57BL/6 background) exhibit increased alveolar hemorrhage compared with control mice when challenged with intratracheal LPS (Table 2) . 159 As expected, both low TF and TF fl/fl , SPCcre mice had increased alveolar hemorrhage after influenza A virus infection (Tables 2 and 3 ). 160 However, significantly more bleeding was observed in low TF mice compared with TF fl/fl , SPCcre mice, and we hypothesize that additional cell types, such as fibroblasts, also contribute to hemostasis in the lung. We are currently testing this hypothesis.
Brain
The brain contains high levels of TF with astrocytes being the major source. 184, 185 Low TF mice occasionally succumb to spontaneous fatal brain hemorrhages (Table 2) . 152, 154 In addition, administration of an antihuman TF antibody to TF knockin mice expressing hTF resulted in cerebral hemorrhage. 164 Importantly, FVII −/− and FII −/− neonates also have fatal cerebral hemorrhages. 126, 129, 130 In addition, genetic elimination of FII in adult mice led to spontaneous hemorrhage in the brain. 186, 187 Recently, the Pawlinski group generated mice with TF deleted in all neuronal cells (TF fl/fl , nestin-cre; Table 3 ).
172 These mice express a very low level of TF (≈1%) in their brains compared with a slightly higher level of TF (≈2%) in the brains of low TF mice. A model of collagenase-induced intracerebral hemorrhage was used to determine the role of TF in brain hemostasis. Both low TF and TF fl/fl , nestin-cre mice exhibited increased intracerebral hemorrhage compared with controls. 172 However, more hemorrhage was observed in TF fl/fl , nestin-cre compared with low TF mice and this was associated with death of some of these mice. These studies suggest that the high levels of TF in the brain are required to limit intracerebral hemorrhage after traumatic brain injury.
Heart
TF is expressed by both cardiac fibroblasts and cardiac myocytes in the heart. 184 Administration of an inhibitory antihuman TF antibody to TF knockin mice expressing HTF resulted in cardiac hemorrhage. 164 We have observed occasional spontaneous hemorrhages in the heart of low TF mice and hearts of older low TF mice are fibrotic. 158 Mice with only ≈20% expression of hTF in the heart and those with TF deleted in cardiac myocytes (TF fl/fl , Mlc2v; Table 3 ) also exhibit cardiac fibrosis. 157 Importantly, a similar pattern of cardiac fibrosis has been observed in low FVII, low FX, and low FII expressing mice but not FIX deficient mice. 133, 153, 188, 189 Spontaneous hemorrhage was also observed in the heart after genetic elimination of prothrombin in adult mice. 186 These results indicate that the extrinsic pathway, but not the intrinsic pathway, mediates cardiac hemostasis. 153, 158, 186, 188, 189 
Uterus, Placenta, and Testis
Female low TF mice exhibit excess bleeding after delivery and 14% of the mice die, which indicates that TF is required for uterine epithelium hemostasis postpartum (Table 2) . 156 Low TF placentas contain blood pools in the labyrinth (Table 2) . 156 At present, it is unclear whether this is because of a hemostatic defect or a structural defect in the placental labyrinth. Interestingly, FVIII −/− and FIX −/− mice have no hemostatic defects in the uterus or placenta. 132, 133 We observed that male low TF mice lost fecundity at a relatively young age and had shrunken and fibrotic testes. We also observed spontaneous hemorrhage in the testes of low TF mice that may have been induced by trauma or during retraction of the testes into the abdomen. We think that hemorrhage leads to fibrosis of the testes and the loss of fertility.
Thrombosis
Thrombosis is a pathological process that occludes blood flow in vessels. TF is involved in the pathogenesis of both arterial and venous thrombosis. 190 Sources of TF that activate coagulation in different diseases include macrophages and microvesicles in atherosclerotic plaques, activated cells within the vasculature and perivascular cells that are exposed because of an increase in vascular permeability.
There is strong evidence that monocyte TF contributes to thrombosis in many diseases (Table 4) .
Atherosclerosis
In humans, rupture of advanced atherosclerotic lesions triggers arterial thrombosis leading to myocardial infarction and stroke. Atheroma contain high levels of TF that likely plays a central role in atherothrombosis ( Figure 3A) . 191, [204] [205] [206] [207] [208] [209] [210] Macrophage foam cells are the main source of TF in plaques with apoptotic macrophages releasing TF-positive microvesicles into the necrotic core. 192, 193, 211 In addition, patients with acute coronary syndromes have increased levels of TF expression in monocytes, platelets, and leukocyte-platelet aggregates that may also contribute to thrombosis after plaque rupture. 48, 212 Many studies have reported increased levels of TF antigen in the plasma of cardiovascular disease patients. 213 However, we could not detect increased levels of microvesicle TF activity in these patients. 214 In mice a 50% reduction of TFPI increased thrombosis after photochemical disruption of carotid artery plaques in ApoE −/− mice, presumably because of an increase in TF PCA. 215 Importantly, inhibition of TF with FVIIai markedly reduced thrombosis after ultrasonic disruption of carotid plaques in ApoE −/− mice. 216 Similarly, FVIIai or recombinant TFPI reduced thrombosis after balloon-mediated disruption of carotid plaques in hypercholesterolemic rabbits. 217, 218 These studies indicate that TF within atherosclerotic plaques plays a major role in the formation of occlusive thrombi after rupture.
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Sepsis/Endotoxemia
Disseminated intravascular coagulation is a life-threatening disorder caused by diffuse activation of coagulation that can result in microvascular occlusion and organ dysfunction. 220 Disseminated intravascular coagulation is frequently observed in patients with bacterial sepsis. TF has been shown to play a central role in disseminated intravascular coagulation ( Figure 3B ). 221 In a human model of LPS-induced endotoxemia TF mRNA and TF protein expression were induced in blood cells (presumably monocytes) and this was associated with increased levels of thrombin-antithrombin complex, a marker of activation of coagulation. 39 TF expression is also observed in monocytes isolated from septic baboons. 40 As noted earlier, immunohistochemistry studies demonstrated TF staining on ECs in the spleen and aorta of septic baboons and ECs in the glomerulus of endotoxemic mice. 38, 80, 83 Therefore, EC TF may also play a role the activation of coagulation during sepsis and endotoxemia. Importantly, early inhibition of TF reduced the activation of coagulation and mortality in septic baboons. 107, 222 We analyzed the role of TF in the activation of coagulation in a mouse model of endotoxemia. As expected, LPS activation of coagulation was lower in low TF mice compared with controls. 223 Similarly, wild-type mice containing bone marrow from low TF mice or mice with TF deleted in myeloid cells (TF fl/fl , LysMCre; Table 2 ) had lower levels of activation of coagulation compared with controls. 168 However, bone marrow cells only account for ≈50% of TF that activates coagulation in endotoxemic mice. We found that deleting TF on ECs did not affect activation of coagulation in a mouse endotoxemia model. 168 Another study found that inducible expression of a degradation resistant form of IκBα in ECs blocked the induction of TF expression in ECs in the glomerulus of endotoxemic mice. 83 However, the specific impact of this blockade of EC TF expression could not be evaluated because expression of the mutant IκBα also prevented the downregulation of the anticoagulant proteins EC protein C receptor and thrombomodulin. 83 Taken together, we propose that activated monocytes are the major source of TF that activates coagulation during endotoxemia and sepsis. However, we speculate that TF expressed on perivascular cells exposed by increased vascular permeability and possibly TF induced on ECs also contribute to the activation of coagulation in sepsis.
Surgery
Surgery is associated with an increased risk of venous thrombosis. Three studies have reported an increase in monocyte TF expression 1 day after surgery to remove tumors as well as after coronary artery bypass surgery and total knee arthroplasty. 194, 224, 225 This suggests that surgery triggers an inflammatory response surgery that induces monocyte TF expression. Importantly, the increase in monocyte TF occurs before the peak of clinical venous thrombosis, which is 7 days after surgery. 226 These studies suggest that induction of TF expression on monocytes contributes to postsurgery venous thrombosis.
Cancer
Thromboembolism represents a leading cause of death in patients with cancer and is associated with poor prognosis. Venous thrombosis, in particular, is frequently observed in cancer patients with reported annual incidences ranging between 1.5% to 20% per annum depending on the site of cancer and treatment. 228 In vitro, cancer cell lines shed TF-positive microvesicles. 68, [229] [230] [231] Moreover, increased levels of circulating TF-positive microvesicles are observed in patient with different types of cancer, including pancreatic, brain, colorectal, lung, breast, and prostate. 195, [232] [233] [234] [235] Importantly, elevated levels of MV TF activity are associated with venous thromboembolism in pancreatic cancer patients but not in brain, gastric, or colorectal cancer patients. [195] [196] [197] 228 Preclinical studies of cancer-associated thrombosis have largely focused on pancreatic cancer, given the high rates of thrombosis observed in patients with this type of malignancy. Immunocompetent and immunodeficient mouse models have been used to study the role of tumor-derived, TF-positive microvesicles in thrombosis ( Figure 3C ). Studies have used the mouse pancreatic cell line Panc02 that expresses TF. Injection of mice with Panc02-derived, TF-positive microvesicles enhanced thrombosis in a laser injury model and an infrarenal vena cava (IVC) stenosis model, whereas microvesicles from Panc02 cells with reduced TF expression were less thrombotic. 236, 237 Moreover, immunocompetent mice bearing Panc02 tumors had enhanced thrombus formation in a mesenteric ferric chloride model and an IVC stenosis model. 236, 237 Immunodeficient mice are required for studies with human pancreatic cancer cell lines. We and others have used several TF-expressing human pancreatic cells lines, including L3.6pl, HPAF-II, and BxPc-3. 68, 238, 239 Injection of TF-positive microvesicles derived from these cell lines activated coagulation and increased thrombus formation in the IVC stenosis model. 68, 238, 239 In addition, inhibition of TF on BxPc-3 microvesicles with an antihuman TF antibody abolished the enhanced thrombosis. Mice bearing HPAF-II tumors also demonstrated markedly shortened time to occlusion in a saphenous vein ferric chloride injury model but there was no increase in thrombosis in the IVC stenosis model. 68 However, mice bearing BxPc-3 tumors had an increase in thrombosis in the IVC stenosis model. 238 Recently, we evaluated the contribution of tumor derived, TF-positive microvesicles to venous thrombus in tumor bearing mice. 240 Mice with orthotopic BxPc-3 tumors had larger thrombi in an IVC stasis model compared with controls and administration of an antihuman TF antibody significantly reduced the size of the thrombi. 240 Taken together, these studies suggest that tumors release TF-positive microvesicles into the circulation and that these microvesicles enhance venous thrombosis.
Antiphospholipid Syndrome
Antiphospholipid syndrome (APS) is an autoimmune disorder caused by the development of antibodies against many phospholipids, such as cardiolipin, phospholipid-associated proteins, including β 2 -glycoprotein I, and plasma proteins, such as prothrombin. 241 Collectively, these antibodies are called antiphospholipid antibodies (aPLA). APS patients with persistently high titers of aPLA are at significant risk of arterial and venous thromboembolic events and fetal loss. 242 The exact mechanism by which aPLA induce a hypercoaguable state remains unclear. However, results from different studies suggest that aPLA induction of TF expression in monocytes may underpin the pathogenesis of APS-associated thrombosis. Importantly, human monocytes isolated from patients with APS express TF. [198] [199] [200] Moreover, incubation of primary human monocytes from healthy individuals with anti-β 2 -glycoprotein I IgG leads to increased monocyte TF gene expression, PCA and release of TF-positive microvesicles. [243] [244] [245] [246] In vitro studies showed that aPLA induces oxidative stress in monocytes, and levels of cell surface TF exposure correlate with intracellular peroxide generation. 247 Furthermore, pretreatment of the monocytes with the antioxidant ubiquinol, reduced Coenzyme Q 10 , decreased oxidative stress and TF expression. 248 In a follow-up study, administration of Coenzyme Q 10 to APS patients reduced oxidative stress and TF exposure on monocytes. 248, 249 Further clinical studies are required to determine if antioxidant therapies can effectively prevent thrombotic events in patients with APS by reducing monocyte TF expression.
Animal models have been used to gain insights into the involvement of TF in APS-associated thrombosis ( Figure 3D) . 250, 251 For instance, low TF mice were protected from the thrombotic microangiopathy induced by the passive transfer of a murine monoclonal aPLA or purified patient aPLA. 252 Interestingly, aPLA were shown to induce TF expression in monocytes and ECs via a pathway involving endosomal NADPH oxidase and TLR7/8. 253 Importantly induction of TF was absent in aPLA-treated monocytes from NOX2 −/− mice. A follow-up study with mice showed that aPLA enhanced thrombosis in an IVC stenosis model. 254 Enhanced thrombosis in this study required NOX2 and leukocytes but not TLR4 or platelets. 250 These 2 studies suggest a role for monocyte TF in aPLA induced thrombosis. 254 Further studies are needed to understand how TF contributes to thrombosis in patients with APS.
Acute Liver Injury and Cirrhosis
Acute liver injury and cirrhosis are associated with a prothrombotic state. One study found very high levels of circulating MV TF activity in patients with acute liver injury. 255 We found that MV TF activity was increased with cirrhosis and levels were associated with the Child-Pugh score and markers of activation of coagulation and fibrin degradation. 256 The liver expresses low levels of TF compared with other organs, such as the brain and lung. The Luyendyk group determined the contribution of hepatocytes to basal TF expression in the liver by comparing levels in mice with TF deleted in hepatocytes (TF fl/fl , Albcre) to controls (Table 3) . Importantly, we found a dramatic reduction of TF in TF fl/fl , Albcre mice indicating that hepatocytes are the major source of TF in the liver. 169 Furthermore, administration of acetaminophen to wild-type but not TF fl/fl , Albcre mice led to a rapid activation of coagulation as measured by increased levels of plasma thrombin-antithrombin complexes. 169 In a second study, we used a mouse model of bile duct ligation to determine the cellular source of TF responsible for activation of coagulation in chronic liver injury. As expected, activation of coagulation was lower in low TF mice compared with controls. 170 Interestingly, activation of coagulation was reduced by deletion of TF in hepatocytes but not myeloid cells. 170 These 2 mouse models indicate that de-encryption of hepatocyte TF mediates the rapid activation of coagulation during liver injury.
Sickle Cell Disease
SCD is an autosomal recessive disorder caused by a single point mutation in the β-globin gene. Under hypoxic conditions aggregation of the hemoglobin variant leads to the formation of sickled erythrocytes. Patients with this disorder have an increased risk of both arterial and venous thromboembolic events. [257] [258] [259] SCD patients have increased numbers of monocyte-and EC-derived TF-positive microvesicles and levels were positively correlated with both thrombin-antithrombin and D-Dimer, which suggested that these particles may contribute to the procoagulant state observed in SCD. 201 Mouse models have been used to study the role of TF in the activation of coagulation and inflammation in SCD. Inhibition of TF reduced the chronic procoagulant state and inflammation observed in SCD mice. 73 Furthermore, SCD mice had increased thrombosis in a light-dye-mediated injury to the cerebral microcirculation and this was inhibited by an inhibitory anti-TF antibody. 260 Several studies have investigated the cellular sources of TF expression that contribute to the activation of coagulation in SCD mice. 261 TF expression has been reported in monocytes, neutrophils, and ECs in SCD mice. 73, 81, 82 An early study observed increased TF expression on pulmonary veins of moderate and severe models of SCD whereas hypoxia and reoxygenation was required to increase EC TF expression in a mild model of SCD. 81 We found that deletion of TF in ECs did not affect activation of coagulation in mice with sickle cell bone marrow but reduced levels of interleukin6. 262 Similar results were observed in SCD mice that received the FXa inhibitor rivaroxaban and SCD mice lacking PAR2 in nonhematopoietic cells. 262 These data suggest that a TF-FXa-PAR2 complex on ECs does not contribute to the activation of coagulation but drives interleukin6 expression in SCD.
Viral Infections
Viral infections are associated with activation of coagulation and thrombosis. For instance, infection with hemorrhagic fever viruses, such as Ebola virus, is associated with DIC, whereas HIV infection increases the risk of thrombosis. Viruses induce TF expression in a variety of cells, including monocytes and ECs. 263 Importantly, Ebola virus induced TF mRNA expression in peripheral blood mononuclear cells in vitro and peripheral blood mononuclear cells isolated from infected monkeys. 202 Moreover, inhibition of TF reduced mortality in monkeys infected with Ebola virus. 264 Similarly, monocyte TF expression correlated with levels of HIV and D-dimer in plasma from HIV infected patients. 203 More recently, it was shown that TF is expressed by a subset of monocytes (CD14 + , CD16 − , CCR2 + ) in HIV infected patients, and inhibition of TF reduced D-dimer levels in monkeys infected with simian immunodeficiency virus. 106 These studies suggest that TF expression by monocyte drives the coagulopathy in HIV infected patients.
Conclusions
It is clear that the TF-FVIIa complex is essential for hemostasis and provides additional protection to vital organs, such as the heart, lung, and brain. Further studies are needed to understand the cell types that express TF in different tissues and control hemostasis under basal and pathological conditions. TF contributes to arterial and venous thrombosis. TF also plays a major role in the formation of thrombi after rupture of atherosclerotic plaques. Infection induces TF expression on monocytes and this can trigger DIC. Inhibition of all sources of TF is associated with increased bleeding. However, targeted inhibition of pathological TF expression, for instance in monocytes, may reduce thrombosis associated with different diseases.
